VANDERBILT-INGRAM CANCER CENTER received an overall “exceptional” score as part of the renewal of the Cancer Center Support Grant.
As congressional leaders discuss potential ways to avert a government shutdown, which could happen in less than a week if policymakers are unable to agree to a short-term continuing resolution to keep the government running beyond Sept. 30, I remain optimistic that NIH will receive its largest annual budget increase in 12 years.
CHRISTOPH ZIELINSKI was named editor-in-chief of ESMO Open, a new open-access, peer-reviewed online journal published by the European Society of Medical Oncology.
Amgen Inc. and Xencor Inc. entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation.
Congress must put an end to the emerging practice of “information blocking” by purveyors of electronic health record systems, American Society of Clinical Oncology urged at a Capitol Hill briefing.
ROBERT SCHREIBER and PHILIP GREENBERG were named editors-in-chief of Cancer Immunology Research, one of eight peer-reviewed journals published by the American Association for Cancer Research.
CTI BioPharma Corp. said it plans to submit a new drug application to FDA following a productive pre-NDA meeting for pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R.
Roche NimbleGen introduced an enhanced whole exome sequencing solution for medical and translational research.
ICON, a provider of drug development solutions, said it's working with IBM to help reduce the time and costs of drug development while also offering patients enhanced quality of care by connecting them to relevant clinical trials. ICON said it will tap Watson's cognitive computing power to help the process of identifying patients who meet the criteria for a clinical trial, and to analyze protocols to assess trial feasibility and identify optimal trial sites.
AstraZeneca and Peregrine Pharmaceuticals Inc. entered into a cancer immunotherapy clinical trial collaboration.
